WO2023174941 - FIBRATE COMPOSITIONS FOR TREATING INFLAMMATION AND NEUROINFLAMMATION
National phase entry:
Publication Number
WO/2023/174941
Publication Date
21.09.2023
International Application No.
PCT/EP2023/056491
International Filing Date
14.03.2023
Title **
[English]
FIBRATE COMPOSITIONS FOR TREATING INFLAMMATION AND NEUROINFLAMMATION
[French]
COMPOSITIONS DE FIBRATE POUR TRAITEMENT DE L'INFLAMMATION ET DE LA NEURO-INFLAMMATION
Applicants **
TRX BIOSCIENCES LIMITED
Inventors
BREW, John
GOODING, Daniel
BANNISTER, Robin M.
Priority Data
63/269,327
14.03.2022
US
63/362,005
28.03.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
* |
| Recordal of a Change of the Applicant's Name/Address | * |
| Type of Assignment | * |
| Applicant's Legal Status | * |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under | * |
| Patent Delivery | * |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4929 | |
| EPO | Filing, Examination, Granting | 46570 | |
| Japan | Filing, Examination, Granting | 3753 | |
| South Korea | Filing, Examination, Granting | 5703 | |
| USA | Filing, Examination, Granting | 15290 |

Total:
76,245
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
fatty acid surfactants, or any combination thereof. The present specification also discloses methods and procedures to formulate the disclosed one or more fibrates into the disclosed pharmaceutical compositions. The present specification further discloses methods and uses of the disclosed pharmaceutical compositions in the treatment of an inflammation and/or neuroinflammation.[French]
, ou une combinaison quelconque associée. La présente invention divulgue également des méthodes et des procédures pour formuler le ou les fibrates divulgués dans les compositions pharmaceutiques divulguées. La présente invention divulgue en outre des méthodes et des utilisations des compositions pharmaceutiques divulguées dans le traitement d'une inflammation et/ou d'une neuro-inflammation.